AI-POWR Trademark

Trademark Overview


On Friday, July 3, 2020, a trademark application was filed for AI-POWR with the United States Patent and Trademark Office. The USPTO has given the AI-POWR trademark a serial number of 90035441. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 28, 2023. This trademark is owned by Hepion Pharmaceuticals, Inc.. The AI-POWR trademark is filed in the Computer & Software Products & Electrical & Scientific Products and Computer & Software Services & Scientific Services categories with the following description:

Downloadable and prerecorded computer software using artificial intelligence for precision medicine, namely, to decode diseases, develop targeted pharmaceutical treatments and therapies, and to select patients that will respond to pharmaceutical treatments and therapies; downloadable and prerecorded computer software using artificial intelligence for bioinformatics, simulations in clinical trials or studies, the designing of clinical trials or studies, and the de-risking of clinical trial or study designs and clinical trials simulations; downloadable and prerecorded computer software using artificial intelligence for analyzing non-clinical data, preclinical data, and clinical data, for analyzing the results of clinical trials or studies, for evaluating clinical outcomes and treatment responses, for patient identification and a priori responder selection, for individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determinati...

Design, development, computer programming, testing, maintenance, customization, and operation of computer software in clinical trials or studies; designing clinical trials or studies; clinical research in the field of improving the efficacy of clinical trials and studies and de-risking clinical trial or study designs, clinical trials simulations, and clinical endpoint selection; clinical research, namely, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses; clinical research in the field of patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, ...
ai-powr

General Information


Serial Number90035441
Word MarkAI-POWR
Filing DateFriday, July 3, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 28, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 31, 2022

Trademark Statements


Goods and ServicesDownloadable and prerecorded computer software using artificial intelligence for precision medicine, namely, to decode diseases, develop targeted pharmaceutical treatments and therapies, and to select patients that will respond to pharmaceutical treatments and therapies; downloadable and prerecorded computer software using artificial intelligence for bioinformatics, simulations in clinical trials or studies, the designing of clinical trials or studies, and the de-risking of clinical trial or study designs and clinical trials simulations; downloadable and prerecorded computer software using artificial intelligence for analyzing non-clinical data, preclinical data, and clinical data, for analyzing the results of clinical trials or studies, for evaluating clinical outcomes and treatment responses, for patient identification and a priori responder selection, for individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination; downloadable and prerecorded computer software using artificial intelligence for selection and identification of drugs, drug targets, and drug combination selection and evaluation, for biomarker selection, for genetic data analyses, for omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and for accessing and processing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and for disease and drug analysis in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field; all of the aforesaid excluding computer software for application and database integration
Pseudo MarkAI-POWER
Goods and ServicesDesign, development, computer programming, testing, maintenance, customization, and operation of computer software in clinical trials or studies; designing clinical trials or studies; clinical research in the field of improving the efficacy of clinical trials and studies and de-risking clinical trial or study designs, clinical trials simulations, and clinical endpoint selection; clinical research, namely, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses; clinical research in the field of patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses; consulting, consultancy, and consulting services related to clinical trials or studies, namely, designing clinical trials or studies, de-risking clinical trial or study designs, conducting clinical trials simulations, clinical endpoint selection, analyzing preclinical data and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses; consulting, consultancy, and consulting services related to clinical trials or studies, namely, conducting patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination; platform as a service (PaaS) featuring computer platforms and software using artificial intelligence for precision medicine, namely, to decode diseases, develop targeted pharmaceutical treatments and therapies, and to select patients that will respond to pharmaceutical treatments and therapies; platform as a service (PaaS) featuring computer platforms and software using artificial intelligence for bioinformatics, simulations in clinical trials or studies, the designing of clinical trials or studies, and the de-risking of clinical trial or study designs and clinical trials simulations; platform as a service (PaaS) featuring computer platforms and software using artificial intelligence for analyzing non-clinical data, preclinical data, and clinical data, for analyzing the results of clinical trials or studies, for evaluating clinical outcomes and treatment responses, for patient identification and a priori responder selection, for individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination; platform as a service (PaaS) featuring computer platforms and software using artificial intelligence for selection and identification of drugs, drug targets, and drug combination selection and evaluation, for biomarker selection, for genetic data analyses, for omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and for accessing and processing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and for disease and drug analysis in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field; all of the aforesaid excluding computer software and services for application and database integration

Classification Information


International Class009 - Scientific, nautical, surveying, photographic, cinematographic, optical, weighing, measuring, signalling, checking (supervision), life-saving and teaching apparatus and instruments; apparatus and instruments for conducting, switching, transforming, accumulating, regulating or controlling electricity; apparatus for recording, transmission or reproduction of sound or images; magnetic data carriers, recording discs; automatic vending machines and mechanisms for coin operated apparatus; cash registers, calculating machines, data processing equipment and computers; fire extinguishing apparatus.
US Class Codes021, 023, 026, 036, 038
Class Status Code6 - Active
Class Status DateThursday, July 30, 2020
Primary Code009
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, July 30, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameHepion Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressEdison, NJ 08837

Party NameHepion Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressEdison, NJ 08837

Trademark Events


Event DateEvent Description
Monday, August 28, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, August 28, 2023ABANDONMENT - NO USE STATEMENT FILED
Tuesday, January 17, 2023ASSIGNED TO EXAMINER
Tuesday, December 6, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 1, 2022SOU EXTENSION 1 GRANTED
Thursday, December 1, 2022SOU EXTENSION 1 FILED
Thursday, December 1, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, July 26, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 31, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 31, 2022PUBLISHED FOR OPPOSITION
Wednesday, May 11, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, April 28, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 27, 2022EXAMINER'S AMENDMENT ENTERED
Tuesday, April 26, 2022ASSIGNED TO LIE
Tuesday, April 26, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, April 26, 2022EXAMINERS AMENDMENT E-MAILED
Tuesday, April 26, 2022EXAMINERS AMENDMENT -WRITTEN
Sunday, April 24, 2022NOTIFICATION OF FINAL REFUSAL EMAILED
Sunday, April 24, 2022FINAL REFUSAL E-MAILED
Sunday, April 24, 2022FINAL REFUSAL WRITTEN
Friday, April 15, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, April 15, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, April 15, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, November 2, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, November 1, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, November 1, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, May 6, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, May 6, 2021NON-FINAL ACTION E-MAILED
Thursday, May 6, 2021NON-FINAL ACTION WRITTEN
Friday, April 9, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, April 8, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 8, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, December 30, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, December 30, 2020TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, December 30, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, December 30, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, October 16, 2020NOTIFICATION OF PRIORITY ACTION E-MAILED
Friday, October 16, 2020PRIORITY ACTION E-MAILED
Friday, October 16, 2020PRIORITY ACTION WRITTEN
Friday, October 9, 2020ASSIGNED TO EXAMINER
Thursday, July 30, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, July 7, 2020NEW APPLICATION ENTERED